U.S. License Holder:
Date of License:
HEMLIBRA (emicizumab) is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients age newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
7,033,590 (Factor IX/Factor IXa Activating Antibodies and Antibody Derivatives)
Baxalta GmbH; Baxalta Incorporated
Chugai Pharmaceutical Co., Ltd.; Genentech, Inc.
Federal Circuit Appeal(s)
Final Judgment of Non-Infringement, Counter-claims Dismissed; Federal Circuit Vacated and Remanded, Summary Judgment of Invalidity for Lack of Enablement on Remand; Federal Circuit Appeal of Remand Decision Ongoing